Table 2.

CVD risk by HIV status and inflammatory biomarker profiles.

	Population			Cluster
CVD risk algorithm	Whole study population (n = 312)	People without HIV (n = 94)	People with HIV (n = 218)	Reference (n = 146)	Gut/immune activation (n = 36)	Neurovascular (n = 130)
QRISK
Median (IQR)	9.5 (5.0−15.7)	10.2 (5.5−16.9)	9.3 (4.5−14.7)	7.8 (4.1–12.8)	13.0 (4.7−17.4)	10.7 (5.9−16.2)
Level of risk
Low (<10%)	162 (51.9)	45 (47.9)	117 (53.7)	89 (61.0)	16 (44.4)	57 (43.9)
Moderate (10–20%)	115 (36.9)	35 (37.2)	80 (36.7)	43 (29.5)	15 (41.7)	57 (43.9)
High (≥20%)	35 (11.2)	14 (14.9)	21 (9.6)	14 (9.6)	5 (13.9)	16 (12.3)
FRS
Median (IQR)	11.8 (6.8–18.7)	11.0 (7.3−19.6)	12.1 (6.8−18.4)	10.2 (5.9−16.0)	13.5 (8.2−25.4)	13.6 (8.4−19.9)
Level of risk
Low (<10%)	127 (40.7)	44 (46.8)	83 (38.1)	72 (49.3)	12 (33.3)	43 (33.1)
Moderate (10–20%)	119 (38.1)	29 (30.9)	90 (41.3)	54 (37.0)	10 (27.8)	55 (42.3)
High (≥20%)	66 (21.2)	21 (22.3)	45 (20.6)	20 (13.7)	14 (38.9)	32 (24.6)

	Whole population (n = 218)	People without HIV (n = 94)	People with HIV (n = 218)	Reference (n = 99)	Gut/immune activation (n = 19)	Neurovascular (n = 100)
D:A:D
Median (IQR)	–	–	9.0 (5.0−14.7)	7.3 (4.3−12.4)	14.2 (7.1−19.7)	9.8 (5.8−16.0)
Level of risk	–	–
Low (<10%)	–	–	125 (57.3)	66 (66.7)	7 (36.8)	52 (52.0)
Moderate (10–20%)	–	–	68 (31.2)	24 (24.2)	8 (42.1)	36 (36.0)
High (≥20%)	–	–	25 (11.5)	9 (9.1)	4 (21.1)	12 (12.0)

CVD, cardiovascular disease; D:A:D, Data Collection on Adverse effects of anti-HIV Drugs; FRS, Framingham Risk Score.